BAYER AKTIENGESELLSCHAFT «...678910...» Página 8 de 137 desde 01/07/1988 hasta 15/06/2024 27/11/2018 07:27 BAYER AKTIENGESELLSCHAFT R&D: new licenses, patents and registered trademarks U.S. FDA approves Larotrectinib, the first TRK inhibitor, for patients with advanced solid tumors harboring an NTRK gene fusion Número de registro: 271928 13/11/2018 08:37 BAYER AKTIENGESELLSCHAFT Information on P&L Bayer AG: Public Information refered to Q3-2018 Número de registro: 271479 13/11/2018 07:40 BAYER AKTIENGESELLSCHAFT Information on P&L Bayer: Good performance in a challenging environment, Group outlook confirmed Número de registro: 271477 13/11/2018 07:37 BAYER AKTIENGESELLSCHAFT Information on P&L Bayer: Q3 2018 Analyst and Investor Briefing Número de registro: 271476 30/10/2018 10:24 BAYER AKTIENGESELLSCHAFT Information on P&L Bayer: Q3 2018 Publication Schedule Número de registro: 271009 24/10/2018 15:22 BAYER AKTIENGESELLSCHAFT Information on P&L Bayer: Supplemental information ahead of Q3 2018 results Número de registro: 270802 24/10/2018 07:37 BAYER AKTIENGESELLSCHAFT R&D: new licenses, patents and registered trademarks Phase III trial of darolutamide in patients with non-metastatic castration-resistant prostate cancer meets primary endpoint Número de registro: 270770 22/10/2018 07:26 BAYER AKTIENGESELLSCHAFT R&D: new licenses, patents and registered trademarks Expanded larotrectinib data confirm findings on efficacy and safety in adult and pediatric patients with TRK fusion cancer across various tumor types Número de registro: 270684 12/10/2018 16:52 BAYER AKTIENGESELLSCHAFT R&D: new licenses, patents and registered trademarks U.S. FDA approves Bayer’s Xarelto® for patients with coronary or peripheral artery disease Número de registro: 270462 21/09/2018 15:06 BAYER AKTIENGESELLSCHAFT R&D: new licenses, patents and registered trademarks Bayer receives positive CHMP opinion for its hemophilia A treatment BAY94-9027 Número de registro: 269826 Página 8 de 137 «...678910...»
